Semax research overview: evidence, Russian approval, US status

Key points

• Semax is a seven-amino-acid peptide developed in Moscow. In Russia it is a prescription nasal-drop medicine (0.1% and 1%) made by Peptogen [7][8][2].
• The human evidence is Russian, mostly small, and mostly open-label or loosely controlled. We found no Semax study on ClinicalTrials.gov and no large English-language randomized trial [26][27].
• Semax is not FDA-approved. FDA staff proposed keeping it off the compounding “503A bulks list”; an advisory committee voted 8-5 the other way on 24 July 2026. That vote is not binding [1][4][5].
• BDNF and gene-expression findings come from rats, mice and cell cultures, not from people.
• The D-tier and “cope” rankings cite no evidence; verdicts are at the end.

What Semax is and where it came from

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (molecular weight about 814 g/mol) [2]. The literature calls it both an analogue of the ACTH(4-10) fragment and “ACTH(4-7)PGP”: the first four residues match ACTH, and a Pro-Gly-Pro tail is added [21][2]. FDA’s reviewers say it is suggested to lack the hormonal activity of full ACTH, citing a 2013 review [2].

It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow; a 1997 review by Ashmarin and Nezavibat’ko describes “15 years” of work on it [20]. In a 2009 interview, the institute’s Myasoedov says the institute licenses Semax to the company Peptogen and receives five percent royalties on sales [25]. The institute, which supplies many of the authors below, therefore has a commercial interest.

Peptogen also produces Selank, a related peptide covered in our Selank overview [25]. The site also has a Semax compound page.

What Russia approved it for

We could not open the Russian State Register of Medicines (GRLS); its search page returned no data. This section rests on two commercial drug references that reproduce manufacturer instructions, so the registration is not verified against the register.

• Form: nasal drops, 0.1% and 1%, in 3 ml bottles; manufacturer Peptogen; dispensed by prescription [7][8]. FDA’s own review also says Semax is “registered” in Russia as 0.1% and 1% nasal drops [2].
• 0.1% indications (Vidal): cognitive and memory disorders in vascular brain disease, the recovery period after stroke, dyscirculatory encephalopathy, transient ischemic attacks, states after head injury, surgery and anesthesia, neurotic disorders, optic nerve atrophy and neuritis, and attention-deficit disorder in children [8]. The minimum age is 7 on Vidal and 5 on RLS, likely different instruction versions [7][8].
• 1% indication (RLS): acute ischemic stroke [7].
• Registration number: Vidal lists ЛП-№(009449)-(РГ-RU) dated 26 March 2025 for the 0.1% drops [8]. We could not check it. We could not verify the year of first registration.

What the human studies found

Each row is what the authors reported in the abstract. None of the abstracts states funding or conflicts of interest.

Study	Who and how many	Design and controls	Reported outcome
Gusev et al., 1997 [9]	30 patients with acute ischemic stroke vs 80 controls	“Controlled clinical trial”; controls matched on severity and site; randomization and blinding not described	Faster recovery of neurological function, mainly motor
Gusev et al., 2018 [10]	110 after ischemic stroke, 5 months	Early vs late rehabilitation, each with or without Semax; Pirogov University and a Moscow rehabilitation centre; no placebo or randomization described	Higher plasma BDNF; faster and better Barthel score; smaller effect on paresis
Gusev et al., 2005 [11]	187 with cerebrovascular insufficiency	Comparative; control not described	Authors report improvement and fewer strokes and TIAs
Alekseeva et al., 1999 [15]	73 with post-hypoxic encephalopathy	Comparative; control not described	“Effective” for memory disorders; paroxysmal EEG activity in some patients
Polunin et al., 2000 [12]	Optic nerve disease; size not in abstract	Three groups (two routes, one control), added to basic therapy	Better acuity, visual field and colour vision
Dragon et al., 2022 [14]	60 with vascular optic neuropathy	Semax was one part of a package (magnetic stimulation, oxygen chamber, acupuncture) vs vitamins	“Efficacy” 83-94% vs 30-42%; Semax cannot be separated out
Lebedeva et al., 2018 [17]	24 healthy adults	14 Semax, 10 placebo; resting-state fMRI	Larger frontal part of the default-mode network; no cognitive test reported
Serdyuk et al., 2007 [16]	27 with motor neuron disease	Open-label, sequential groups	No effect on disease course; quality-of-life score improved

Kurysheva et al. (2001) reported better electrophysiology in glaucoma patients with normal eye pressure, without numbers in the abstract [13]. Smaller reports cover peptic ulcer, psoriasis lipids and diabetic retinopathy [30][31][32].

A 2018 meta-analysis by Shmonin and colleagues (St Petersburg, Russian journal) searched 364 records, found 8 eligible studies (654 patients), and pooled 3 (181 patients). It reported lower stroke severity scores and better mobility, and itself called for a multicenter double-blind trial [18]. In July 2026 a Russian pediatric-neurology expert council put Semax in a group with “a limited evidence base” for adjunct ADHD therapy [19].

FDA reviewed Semax in 2026 for cerebral ischemia, migraine and trigeminal neuralgia. It set aside the Russian-language stroke papers because full texts were unavailable in English, and judged the evidence insufficient for all three uses. For migraine and trigeminal neuralgia it found one small, unblinded, uncontrolled study (Koroleva 1996) in which most patients were not pain-free [2].

Animal and cell work (not human evidence)

• BDNF, rat: a 2006 Institute of Molecular Genetics study reported that one intranasal application raised hippocampal BDNF protein up to 1.4-fold and exon III BDNF mRNA about 3-fold [21]. A second 2006 paper found specific binding sites and higher BDNF in the basal forebrain but not the cerebellum [22].
• Gene expression, rat: a 2014 paper reported changed expression of immune and vascular genes in a focal-ischemia model [33]. FDA cites antioxidant action and gene modulation as the likely route of the anti-ischemic effects [2].
• Enzymes and dopamine, in vitro and mouse: FDA lists weak enkephalinase inhibition (about 10 µM) and a mouse finding that Semax potentiated amphetamine-induced dopamine release, and notes that dose-response relationships and effective exposures are unknown [2].
• Independent group, mouse and PC12 cells: a 2025 paper from Fudan University reported better recovery after spinal cord injury and proposed the μ-opioid receptor as a target [23].
• Distribution: in rats, nasal dosing delivered a higher share to the brain than intravenous dosing, and Semax was quickly broken down to Pro-Gly-Pro. FDA found no published human pharmacokinetic study [2].

Status in the US, EU and UK

• United States (FDA, 24 July 2026): Semax is not a component of any FDA-approved drug and has no USP monograph [2]. Two nominations to the 503A bulks list were withdrawn; FDA evaluated it anyway and proposed listing neither Semax free base nor Semax acetate, calling both “not well-characterized” (missing impurity, aggregate and endotoxin data; possible immunogenicity) [1][2].
• Advisory vote: the Pharmacy Compounding Advisory Committee voted 8-5 in favor of adding Semax, according to DLA Piper and RAPS [4][5]. Healio reports 8-5-1; a law-firm summary of all seven votes lists 8-5 with one abstention, so these are the same vote [34]. FDA’s meeting page, as we read it, listed no vote results [3]. The vote is non-binding; rulemaking would be needed, and we found no proposed rule as of 8 November 2026. Scheduling status was not checked.
• EU, UK, Germany: we did not search the EMA, MHRA or BfArM registers (the EMA search page required authentication) and found no regulator statement. FDA notes Semax is not in the European, Japanese or International Pharmacopoeias [2].

How “research use only” products relate to the Russian medicine

“Research use only” is a seller’s label: the product is not sold as a medicine and is not made or tested to medicine standards. FDA says some online sellers list Semax that way, alongside injectable and nasal products offered by clinics [2]. The Semax vial in @Hoostethics’s image carries the words “for research purposes only”.

These are different products from the Peptogen drops. The Russian studies used the Russian medicine in patients; FDA found that nominators’ certificates of analysis lacked impurity and endotoxin data [2]. A 2020 Belgian paper (Sciensano) found Semax and Selank in two seized preparations, and said the peptides had, “to our knowledge”, not completed clinical trials, although Russian studies exist [24]. Evidence on the drops does not transfer to a powder of unknown purity.

Risks and unknowns

• Documented: the Russian label lists mild nasal-mucosa irritation with prolonged use [7][8]. The 1999 encephalopathy study saw paroxysmal EEG activity in some patients after an injection [15]. The developers’ 1997 review said no negative effects occurred [20].
• FDA concerns: no human pharmacokinetics, immunogenicity data or injection safety data, and a meeting abstract suggesting antithrombotic effects, which raises a bleeding question [2]. One adverse-event report (May 2025) described eye pain and burning, hospitalization and symptoms lasting a year after Semax drops bought online. Voluntary reports do not establish cause [2].
• At-risk groups: the Russian label excludes pregnancy, lactation, seizure history, anxiety disorders and acute psychosis [7][8].
• Not studied: long-term use, cognition in healthy adults (beyond the 24-person fMRI study and a 19-man abstract FDA cites), interactions, and quality of non-Russian supply.

Evidence gaps

On 8 November 2026 PubMed held 210 records with “semax” in the title or abstract; one was tagged as a randomized trial and none as a systematic review or meta-analysis [27]. That one (motor neuron disease) describes itself as open-label [16]. ClinicalTrials.gov returned no study for “semax” [26], though Russian trials may be registered elsewhere. We found no head-to-head or healthy-adult cognition trial.

What the tier lists claim

Post text was read through the fxtwitter mirror; we checked the Semax placement in the images.

@dex7official, “the only true cognitive enhancement tier list (no copes edition)”, 20 October 2026, puts Semax and Selank in D, with modafinil [28]. Verdict: could not be verified. No study ranks Semax against anything on that list, and the list gives no criteria. Evidence for cognitive gains in healthy adults is thin, so a low placement is not contradicted.

@Hoostethics, “ranking the most cope supplements”, 15 October 2026, puts Semax in “cope”, the fourth of five tiers [29]. Verdict: partly supported. Evidence of a cognitive benefit in healthy people is essentially absent. But “cope” implies the effect is imagined; no adequate placebo-controlled trial shows that either, and the Russian patient studies can neither rule out placebo nor prove an effect. Both posters rate vials, not the Russian drops.

Frequently asked questions

Is Semax approved? In Russia it is registered as 0.1% and 1% prescription nasal drops for neurological and eye conditions, per two reference sites; we could not open the register [2][7][8]. It is not FDA-approved. EU and UK status was not checked.

Did FDA allow compounding of Semax? No. An advisory committee voted 8-5 in favor on 24 July 2026, against FDA staff’s proposal, but the vote is non-binding and we found no rule [1][4][5].

Does Semax raise BDNF in people? One 110-patient stroke study without a described placebo reported higher plasma BDNF; the brain-tissue findings are from rats [10][21].

Is there a large randomized trial? Not in English, and we found none registered on ClinicalTrials.gov [26][27].

Sources

1. FDA, “FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026”. https://www.fda.gov/media/193342/download (used for FDA’s proposal and withdrawn nominations)
2. FDA, “Semax-related Bulk Drug Substances: Semax (Free Base) and Semax Acetate”, presentation slides (24 July 2026), within https://www.fda.gov/media/193774/download
3. FDA, “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee” (page current as of 6 Aug 2026). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
4. DLA Piper, “FDA AdComm recommends adding six peptides to bulk list” (31 July 2026). https://www.dlapiper.com/insights/publications/2026/07/fda-adcomm-recommends-adding-six-peptides-to-bulk-list
5. RAPS, “FDA advisory committee backs two more peptides, rejects one for compounding list” (undated page, reports the 24 July 2026 vote). https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html
6. Healio, “FDA committee recommends looser restrictions for several peptides” (24 July 2026). https://www.healio.com/news/primary-care/20260724/fda-committee-recommends-looser-restrictions-for-several-peptides
7. RLS (rlsnet.ru), “Семакс” nasal drops (page updated 15 May 2026; instruction of 2008). https://www.rlsnet.ru/drugs/semaks-5536 and https://www.rlsnet.ru/drugs/semaks-5420
8. Vidal (vidal.ru), “Семакс капли назальные 0.1%”. https://www.vidal.ru/drugs/semax__28676
9. Gusev et al., Zh Nevrol Psikhiatr Korsakova (1997), PMID 11517472. https://pubmed.ncbi.nlm.nih.gov/11517472/
10. Gusev et al., Zh Nevrol Psikhiatr Korsakova (2018), PMID 29798983. https://pubmed.ncbi.nlm.nih.gov/29798983/
11. Gusev et al., Zh Nevrol Psikhiatr Korsakova (2005), PMID 15792140. https://pubmed.ncbi.nlm.nih.gov/15792140/
12. Polunin et al., Vestn Oftalmol (2000), PMID 10741256. https://pubmed.ncbi.nlm.nih.gov/10741256/
13. Kurysheva et al., Vestn Oftalmol (2001), PMID 11569188. https://pubmed.ncbi.nlm.nih.gov/11569188/
14. Dragon et al., Vopr Kurortol Fizioter (2022), PMID 36083821. https://pubmed.ncbi.nlm.nih.gov/36083821/
15. Alekseeva et al., Anesteziol Reanimatol (1999), PMID 10199046. https://pubmed.ncbi.nlm.nih.gov/10199046/
16. Serdyuk et al., Zh Nevrol Psikhiatr Korsakova (2007), PMID 18379501. https://pubmed.ncbi.nlm.nih.gov/18379501/
17. Lebedeva et al., Bull Exp Biol Med (2018), PMID 30225715. https://pubmed.ncbi.nlm.nih.gov/30225715/
18. Shmonin et al., “Meta-analysis: Semax effectiveness in the acute period of stroke”, Bulletin of Rehabilitation Medicine 2-84 (2018). https://www.vvmr.ru/en/archives/2018/2-84-aprel-2018/tekhnologii-vosstanovitelnoy-meditsiny-i-meditsinskoy-reabilitatsii/2018-84-metaanaliz-effektivnost-semaksa-v-ostrom-periode-ishemicheskogo-insulta.html
19. Lapochkin et al., “Expert Council resolution: adjunctive pharmacotherapy for ADHD in children”, Zh Nevrol Psikhiatr Korsakova (2026), PMID 42910684. https://pubmed.ncbi.nlm.nih.gov/42910684/
20. Ashmarin and Nezavibat’ko, Zh Vyssh Nerv Deiat (1997), PMID 9173745. https://pubmed.ncbi.nlm.nih.gov/9173745/
21. Dolotov et al., Brain Res (2006), PMID 16996037. https://pubmed.ncbi.nlm.nih.gov/16996037/
22. Dolotov et al., J Neurochem (2006), PMID 16635254. https://pubmed.ncbi.nlm.nih.gov/16635254/
23. Liu et al., Br J Pharmacol (2025), PMID 40692165. https://pubmed.ncbi.nlm.nih.gov/40692165/
24. Vanhee et al., Drug Test Anal (2020), PMID 31667971. https://pubmed.ncbi.nlm.nih.gov/31667971/
25. Vechnaya Molodost, interview with Myasoedov and Kamensky (23 March 2009). https://vechnayamolodost.ru/en/articles/biotechnologies-into-life/protection-of-neuroprotectors/
26. ClinicalTrials.gov API v2, query “semax” (run 8 Nov 2026; zero studies). https://clinicaltrials.gov/api/v2/studies?query.term=semax
27. NCBI PubMed E-utilities, query semax[Title/Abstract] and publication-type filters (run 8 Nov 2026). https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi
28. @dex7official, “THE ONLY TRUE COGNITIVE ENHANCEMENT TIER LIST (NO COPES EDITION)” (20 Oct 2026), read through the fxtwitter mirror. https://x.com/dex7official/status/2112691493261484516
29. @Hoostethics, “ranking the most cope supplements.” (15 Oct 2026), read through the fxtwitter mirror. https://x.com/Hoostethics/status/2110728908735979632
30. Ivanikov et al., Bull Exp Biol Med (2002), PMID 12459874. https://pubmed.ncbi.nlm.nih.gov/12459874/
31. Dontsova, Eksp Klin Farmakol (2015), PMID 27051926. https://pubmed.ncbi.nlm.nih.gov/27051926/
32. Nazarova et al., Vopr Kurortol Fizioter (2013), PMID 24437205. https://pubmed.ncbi.nlm.nih.gov/24437205/
33. Medvedeva et al., “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia” (2014), PMID 24661604 (title and index record only). https://pubmed.ncbi.nlm.nih.gov/24661604/
34. McDermott Will & Schulte, “PCAC backs majority of peptides in two-day public meeting” (2026-07-27; table of all seven substances and votes). https://www.mcdermottlaw.com/insights/blogs/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/

This article is information, not medical advice.